Last reviewed · How we verify

NCT01394107

Evaluation of the LMWH Thromboprophylaxis in Pregnancy

Completed Last updated 15 April 2026
What this trial tests

trial in Pregnancy in 40 participants. Completed in 30 October 2025.

Timeline
1 January 2021
Primary endpoint
31 December 2024
30 October 2025

Quick facts

Lead sponsorCharles University, Czech Republic
StatusCompleted
Study typeOBSERVATIONAL
Enrollment40
Start date1 January 2021
Primary completion31 December 2024
Estimated completion30 October 2025
Sites1 location across Czechia

Conditions studied

Sponsor

Charles University, Czech Republic

Who can join

Adults 18 to 40, female only, with Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The project aims to clarify the effect of the thromboprophylactic LMWH dose on coagulation in pregnant women just before birth, at the period of maximal physiological hypercoagulable state and with high risk of thromboembolism, the most common cause of maternal mortality in developed countries. Although LMWH are now routinely administered as prevention of thromboembolism, their effect on coagulation in pregnant women was not yet studied. The doses of LMWH in pregnancy are only derived in terms of coagulation from totally different groups of patients (surgical, orthopedic). We therefore will map the effect of thromboprophylactic LMWH dose on coagulation in pregnant women using recently available methods, especially a complex examination of coagulation within 24 h after LMWH application using thrombelastography, including examination with heparinase, and monitoring the effect of LMWH by measuring antiXa and TGT (thrombin generation time) activity. Based on these results we will also evaluate the possible influence of LMWH prophylaxis on the risk of spinal haematoma during neuraxial analgesia/anesthesia for delivery/Caesarean section. On the basis of our pilot results we can presume the current dosage of LMWH in pregnant women is inadequate and that it would be appropriate to adjust presently used dosage. At the same time we want to prove that the standard LMWH thromboprophylaxis in pregnant women does not increase the risk of spinal haematoma during neuraxial blockade. In both situations the targeted outcome is to increase the safety of pregnant women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pregnancy

Currently open trials in the same condition.

Other Charles University, Czech Republic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01394107.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing